Peer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain
The publication comes as Lifeward continues to expand commercial access to ReWalk.
ReWalk sales increased 13% year-over-year to $2.5 million in the second quarter of 2026, contributing to a 16% increase in total Lifeward revenue to $6.6 million.
The Company is expanding its capital-efficient channel distribution strategy, including an August 2026 pilot with Ottobock Care, a leading U.S. mobility technology patient care organization with more than 50 patient clinics nationwide, designed to broaden access to ReWalk.
Read More
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.